关于AD8作为痴呆症查工具的重新评估研究和文献综述
Cho-Hsiang Yang1,2, Yi-Ting Lin2,3, Ming H Hsieh2,3
1Department of Psychiatry, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan.
PloS one
|May 5, 2025
概括
八项信息采访以区分衰老和痴呆症 (AD8) 查工具可能在精确识别痴呆症的截止分数为4时表现最好. 这一修订的切断值提高了临床实践中的诊断准确性.
科学领域:
- 老年医学 老年医学
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
背景情况:
- 八项信息采访以区分衰老和痴呆症 (AD8) 是一种痴呆症查工具.
- 最初的研究表明截止分数为2,但这导致了各种人群中的高虚假阳性率.
- 台湾的AD8自我管理也显示出高的假阳性率.
研究的目的:
- 为了评估AD8选工具的性能.
- 为了确定 AD8.8 的最佳切割值.
- 确定影响AD8性能及其临床实用性的因素.
主要方法:
- 从一所大学教学医院招募了118个参与者-告知者二元组.
- 在临床痴呆症评级 (CDR) 之前,AD8被给予信息者,以尽量减少回忆偏差.
- 老年精神病学家提供了基于DSM-5标准的共识诊断;使用了接收器操作特征 (ROC) 分析.
主要成果:
- 对于在CDR 0和CDR 0.5之间进行区分,最佳的AD8切线为2.
- 当包括CDR≥1时,最佳切线转移到3.
- 为了区分正常认知和痴呆症 (DSM-5标准),AD8截止值为4最大化了尤登指数,平衡了灵敏度和特异性.
结论:
- 对AD8的最佳切断值可能因预期的诊断目的而有所不同.
- 建议AD8的截止分数为4,以有效区分患有痴呆症和没有痴呆症的人.
- 这一修订的切线可能会提高临床环境中痴呆症查的准确性.
更多相关视频
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
7.3K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.1K
相关概念视频
Alzheimer's Disease: Overview
358
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
358
Alzheimer's Disease: Treatment
134
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
134
